Ampersand Biomedicines Acquires Abcheck To Accelerate Platform And Product Development
Jan 03, 2024•almost 2 years ago
Acquiring Company
Ampersand Biomedicines
Acquired Company
AbCheck s.r.o.
Description
Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the acquisition of AbCheck s.r.o., a technology company with a suite of antibody discovery technologies for challenging targets and a wholly-owned subsidiary of Affimed GmbH. The addition of AbCheck’s broad discovery platform and deep expertise in antibody generation and optimization will enable cost-effective and strategic acceleration of Ampersand’s Address, Navigate, Determine (AND)TM Platform.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed